Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversion
HONG KONG, Jun 4, 2026 – (ACN Newswire) – Everest Medicines (HKEX 1952.HK) announced that it…